Canada's regulatory body Health Canada recently approved GLP-1 pill developed by pharmaceutical company Eli Lilly. The weight loss pill offers an alternative to injectable weight-loss and diabetes medications. The development comes as new study suggests that GLP-1 drugs could be more effective than metformin in preventing Type 2 diabetes and improving blood sugar in people with obesity and prediabetes.The newly approved drug, Foundayo (orforglipron) is approved for adults with obesity and have at least one related health condition. It is also approved to help manage Type 2 diabetes.Unlike popular GLP-1 medications like Ozempic and Wegovy, which are administered through injections, Foundayo is taken orally once a day. The company expects the GLP-1 pill to become available in Canadian pharmacies in January 2027.How Does Foundayo Work?Also read: Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows PromiseFoundayo contains orforglipron, a non-peptide GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1 (GLP-1), which is naturally-occurring hormone released by the gut after eating.GLP-1 helps regulate blood sugar by stimulating insulin release when glucose levels increase. It also suppresses glucagon, a hormone that raises blood sugar, slows emptying of stomach and targets areas of the brain responsible for appetite. These effects, together, help improve blood sugar control, reduce hunger and support weight loss.Unlike peptide-based GLP-1 medicines, orforglipron is a small molecule that can be absorbed orally without being broken down by digestive enzymes. It can also be taken without the food and water restrictions that come with some oral GLP-1 medications.Novo Nordisk’s Rybelsus is already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.Can GLP-1 Drugs Outperform Metformin?Also read: New Chinese Weight-Loss Injection Ribupatide Shows Over 17% Weight Loss In 48 Weeks: Could It Rival Mounjaro?A separate study presented at the American Heart Association's Scientific Sessions 2026 compared GLP-1 medications to metformin in more than 256,000 adults with obesity and prediabetes.Researchers found that people taking GLP-1 medications were 1.5 times more likely to return to normal blood sugar levels than those taking metformin. They also had a 31% lower risk of developing Type 2 diabetes and a 41% lower risk of death from any cause. GLP-1 users were also at lower risks of heart attacks, strokes and heart failure events.But the study analysed health records rather than conducting a randomised clinical trial. It also grouped several GLP-1 medicines together, including semaglutide, tirzepatide, liraglutide and dulaglutide. Orforglipron was not among the drugs evaluated.Study author Vinicius de Sousa Barzon Serra said, "Metformin is still a first-line treatment choice. It is safe, inexpensive and has a long track record. This is less about replacing one medication with another and more about discussing additional options with specific patients." Side Effects Of GLP-1 MedicationsCommon side effects of GLP-1 medications include gastrointestinal effects like nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These symptoms are often more noticeable when treatment begins or doses increase.Although oral medicines offer an alternative to injections, they are not suitable for everyone. It depend on a person's medical history, blood sugar levels, weight and other health conditions.